Carl Neil Kraus
Principal investigator.
Biotech
Built from public records only: federal awards, patents, filings and papers.Is this you? Contact Noair Lab to claim this profile, correct it or hide it.
2018First federal award
$2.6MFederal grants as PI7 awards
0Patents grantedNone matched
0PapersOpenAlex
Federal awards and patents by year
AwardsPatents
7 awards · $2.6M
| Date | Agency | Award | Amount | Company |
|---|---|---|---|---|
| Apr 4, 2023 | NIH | STTR Phase I Leptin Receptor Agonist to Treat Sleep Disordered Breathing | $320K | Arrevus, Inc. |
| Aug 31, 2022 | NIH | STTR Phase I Leptin Receptor Agonist as a Novel Prevention of Opioid Induced Respiratory Depression | $319K | Arrevus, Inc. |
| May 20, 2020 | NIH | STTR Phase I Development of a Designer Proline-rich antimicrobial peptide Chaperone protein inhibitor (DPC) for treating sepsis | $300K | Arrevus, Inc. |
| Mar 26, 2019 | NIH | STTR Phase I Use of a Designer Proline-rich antimicrobial peptide Chaperone protein inhibitor (DPC) for treating antibiotic resistant pneumonia | $295K | Arrevus, Inc. |
| Feb 1, 2019 | NIH | STTR Phase II Development of a Designer Proline-rich antimicrobial peptide Chaperone protein inhibitor (DPC) for treating multi-drug resistant bacteremia | $739K | Arrevus, Inc. |
| Jun 7, 2018 | NIH | STTR Phase I Development of a Designer Proline-rich antimicrobial peptide Chaperone protein inhibitor (DPC) for treating multi-drug resistant urinary tract infections | $295K | Arrevus, Inc. |
| Feb 5, 2018 | NIH | STTR Phase II Development of a Designer Proline-rich antimicrobial peptide Chaperone protein inhibitor (DPC) for treating multi-drug resistant bacteremia | $297K | Arrevus, Inc. |
Peer ranks
Federal funding#743
Awards as PI#250
Patents#273
Companies
- Arrevus, Inc.Linked by awards · Biotech
Federal awards through Oct 21, 2026 and patents through Oct 20, 2026. Awards come from NIH, NSF and other agency records that name a principal investigator; DoD and NASA contract awards do not, so they are not shown here. Researchers are matched by name and company.